NON INVASIVE DIABETES THERAPY MARKET ANALYSIS

Market News

Key Developments

Continuous research and development activities are expected to drive growth of the non-invasive diabetes therapy market. For instance, in August 2019, a team of researchers tested the efficacy of a new hormone injection that could aid weight loss in obese patients with diabetes. This could potentially serve as a non-invasive alternative for gastric bypass surgery, which are commonly carried out to manage weight and improve blood sugar level in individuals with diabetes.

Moreover, key players in the market are focused on strategic collaborations and agreements to improve their market share. For instance, in July 2019, BioRestorative Therapies, Inc., announced that it had entered a securities purchase agreement with Arena Investors LP. BioRestorative Therapies, Inc. produces non-invasive therapeutics using cell and tissue protocols, and its ThermoStem program is focused on reducing obesity and risk of diabetes.

In July 2019, researchers from the University of Michigan announced an upcoming clinical trial that involves a new non-invasive, endoscopic weight-loss procedure, EndoBarrier developed by GI Dynamics® Inc. The clinical trial of EndoBarrier will include individuals with type 2 diabetes and obesity.